Bozicevic, Field & Francis LLP
High affinity CD47 analogs
High affinity CD47 reagents are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for a SIRPα relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity CD47 reagent, which blocks the physiological binding interaction between SIRPα and a ligand, e.g., native CD47.
The Board of Trustees of the Leland Stanford Junior University
C A A C C C C C A G C
C07K A61K A61K C07K C07K C07K C07K C07K A61K G01N C07K
additional inventional additional additional additional additional inventional inventional inventional inventional inventional
Nan Guo Kipp Andrew Aaron Michael Irving L. Chia Chi Kenan Christopher
Ring Weiskopf Ring Weissman Ho Garcia